Registering a CAGR of 4.7 %over the forecast period, the market value of Mental Disorders Drugs is expected to reach US$ 58.91 billion in the year 2027.
Mental Disorders Drugs Market Overview
The strict stay-at-home orders resulted in limiting the day-to-day activities of individuals. This factor had a major impact on the mental health. Furthermore, job cuts and huge losses in business due to the pandemic turned out to be a major aspect that affected the mental health of numerous people. Hence, the demand for these drugs increased during the pandemic. The fear of mass lockdowns due to the emergence of new variants like Omicron is pushing more people into depression and is increasing the stress levels. These aspects may accelerate the growth of the mental disorder drugs market.
The rising prevalence of mental health conditions such as schizophrenia, bipolar disorder, and depression is contributing to a rise in the use of anti-stress medications. According to the World Health Organization (WHO), depression affects about 264 million people worldwide. Furthermore, according to WHO figures, around 45 million people worldwide are affected by bipolar disorders. Furthermore, according to recent studies, more than 19 million people suffer from schizophrenia, a severe mental health illness. These figures demonstrate the growing demand for mental health treatment, which has a beneficial impact on the global market.
The report aspects discussed the profile of the top manufacturers of the global Mental Disorders Drugs market. These aspects include the financial status of major companies, trending advancements, and the entire market scenario. Growth of the report has examined Mental Disorders Drugs Market production, demand and growth potential, geographic analysis, as well as current market developments in various regions and countries.
Who are the Major Players in Mental Disorders Drugs Market?
The global Mental Disorders Drugs includes identification and analysis of the various market participants competing in the global market. Prominent competitors include Johnson and Johnson, Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb and others.
Industry News and Updates:
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
01/03/2019 - Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share and $50.00 in cash for each share of Celgene. Celgene shareholders will also receive one tradeable Contingent Value Right (CVR) for each share of Celgene, which will entitle the holder to receive a payment for the achievement of future regulatory milestones. The Boards of Directors of both companies have approved the combination.
What are the major Applications, Types and Regions for Mental Disorders Drugs Market?
Market is segmented based on the type, applications, companies and regions.
By Type, it is segmented into
- Children
- Adolescents
- Adults
- Others
By Application, it is segmented into
- Drugs for Schizophrenia
- Antidepressants
- Antipsychotics
- Anxiolytics
- Drugs for the Treatment of Substance and Alcohol Addiction
- Drugs for Childhood and Adolescent Mental Illness
- Drugs to Treat Cognitive Disorders
- Sleep Disorders
- Others
Mental Disorders Drugs Market Regional Analysis
North America is expected to be a major regional contributor to the growth of the mental disorder medications market. Major factors driving the growth of the North American mental disorder pharmaceuticals market include increased awareness about mental health in the countries and increased expenditure in research related to mental health issues.
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Middle East & Africa
- Latin America
The Mental Disorders Drugs Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Mental Disorders Drugs Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
What is our Mental Disorders Drugs Market report scope?
Report Attributes
|
Report Details
|
Forecast Period 2022 to 2027 CAGR
|
CAGR of 4.7% during the review period (2022 to 2027).
|
By Type
|
- Children
- Adolescents
- Adults
- Others
|
By Application
|
- Drugs for Schizophrenia
- Antidepressants
- Antipsychotics
- Anxiolytics
- Drugs for the Treatment of Substance and Alcohol Addiction
- Drugs for Childhood and Adolescent Mental Illness
- Drugs to Treat Cognitive Disorders
- Sleep Disorders
- Others
|
By Companies
|
Johnson and Johnson, Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb and others.
|
Regions Covered
|
- North America
- Europe
- Asia-Pacific
- Rest of the World
|
Countries Covered
|
- US
- Canada
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
|
Base Year
|
2022
|
Historical Year
|
2017 to 2021
|
Forecast Year
|
2022 to 2027
|
Number of Pages
|
139
|
Customization Available
|
Yes, the report can be customized as per your needs
|
Key Takeaways from this Mental Disorders Drugs Report
- Evaluate Mental Disorders Drugs market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level - for product types, end use applications and by different industry verticals.
- Understand the different dynamics influencing the market - growth driving factors, specific challenges and hidden opportunities.
- Get in-depth insights on your competitor performance – revenue, shares, business strategies, financial benchmarking, product benchmarking, SWOT analysis and more.
- Analyze the sales and distribution channels across geographies to enhance top-line revenues.
- Understand the demanding supply chain with a deep dive on the value augmentation at each, in order to optimize value and bring efficiencies in your processes.
- Get a quick outlook on the Mental Disorders Drugs market entropy - M&A's, deals, partnerships, product launches of all key players for the past 5 years.
- Evaluate the import-export statistics, supply-demand and competitive landscape for more than top 20 countries globally for the market.
Frequently Asked Questions
What is the study period of this market?
The Mental Disorders Drugs Market is studied from 2017 - 2027.
What is the growth rate of Mental Disorders Drugs Market?
The Mental Disorders Drugs Market is growing at a CAGR of 4.7% over the next 5 years.
Who are the leading key players in Mental Disorders Drugs Market?
Johnson and Johnson, Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb and others.
What regions regions does this Mental Disorders Drugs Market report covers?
North America (the United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, and Italy)
Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
South America (Brazil, Argentina, Colombia, etc.)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)
What are the significant types of Mental Disorders Drugs Market?
Children, Adolescents, Adults, Others
What are the significant Applications of Mental Disorders Drugs Market?
Drugs for Schizophrenia, Antidepressants, Antipsychotics, Anxiolytics, Drugs for the Treatment of Substance and Alcohol Addiction, Drugs for Childhood and Adolescent Mental Illness, Drugs to Treat Cognitive Disorders, Sleep Disorders, Others
All our reports are custom made to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report as your needs.
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
